Catalog Home Page

Publications: Baker, Ross

Stats for Baker, Ross
Export as [feed] RSS
Group by: Publication Type | Year
Jump to: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
Number of items: 46.


Baker, R., Gilmore, G., Jorritsma, J., Hughes, Q., Tiao, J. and Tay, J. (2017) Circulating MicroRNA as thrombosis sentinels: Caveats and considerations. Seminars in Thrombosis and Hemostasis, In press .

Tay, J. W., James, I., Hughes, Q.W., Tiao, J.Y. and Baker, R.I. (2017) Identification of reference miRNAs in plasma useful for the study of oestrogen-responsive miRNAs associated with acquired Protein S deficiency in pregnancy. BMC Research Notes, 10 (1).

Mahlangu, J.N., Shapiro, A.D., Pasi, K.J., Ragni, M.V., Ozelo, M.C., Oldenburg, J., Matsushita, T., Baker, R.I., Yuan, H., Ferrante, F., Ramirez-Santiago, A., Lethagen, S. and Barnowski, C. (2017) Individualised Prophylaxis with Recombinant Factor IX FC Fusion Protein (RFIXFC) in Adults/Adolescents With Haemophilia B: Updated Interim Results of the B-YOND Extension Study. Haemophilia, 23 (S2). pp. 85-86.


Mahlangu, J., Kuliczkowski, K., Karim, F.A., Stasyshyn, O., Kosinova, M.V., Lepatan, L.M., Skotnicki, A., Boggio, L.N., Klamroth, R., Oldenburg, J., Hellmann, A., Santagostino, E., Baker, R.I., Fischer, K., Gill, J.C., Ng, S.P., Chowdary, P., Escobar, M.A., Khayat, C.D., Rusen, L., Bensen-Kennedy, D., Blackman, N., Limsakun, T., Veldman, A., St. Ledger, K. and Pabinger, I. (2016) Efficacy and safety of rVIII-SingleChain: Results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood, 128 (5). pp. 630-637.

Pasi, K.J., Fischer, K., Ragni, M., Nolan, B., Perry, D.J., Kulkarni, R., Ozelo, M., Mahlangu, J., Shapiro, A.D., Baker, R.I., Bennett, C.M., Barnes, C., Oldenburg, J., Matsushita, T., Yuan, H., Ramirez-Santiago, A., Pierce, G.F., Allen, G. and Mei, B. (2016) Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis, 117 (3). pp. 508-518.

Quon, D.V., Klamroth, R., Kulkarni, R., Shapiro, A.D., Baker, R.I., Castaman, G., Kerlin, B.A., Tsao, E. and Allen, G. (2016) Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. Haemophilia, 23 (1). e39-e42.

Tay, J., Tiao, J., Hughes, Q., Gilmore, G. and Baker, R. (2016) Therapeutic Potential of miR-494 in Thrombosis and Other Diseases: A Review. Australian Journal of Chemistry, 69 (10). pp. 1078-1093.


Metharom, P., Berndt, M.C., Baker, R.I. and Andrews, R.K. (2015) Current state and novel approaches of antiplatelet therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 35 (6). pp. 1327-1338.

Hubbard, A.R., Heath, A.B., Kremer Hovinga, J.A. and Baker, R. (2015) Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 13 (6). pp. 1151-1153.

Qiao, J., Al-Tamimi, M., Baker, R.I., Andrews, R.K. and Gardiner, E.E. (2015) The platelet Fc receptor, FcγRIIa. Immunological Reviews, 268 (1). pp. 241-252.


Oh, D., Huh, J.Y., Chong, S.Y., Kim, I-H, Bang, S-M, Jung, C-W, Lee, J-W, Lee, H.G., Lee, S.M., Kim, Y-K, Park, Y., Jang, S.J., Kim, J-S, Jo, D-Y, Zang, D.Y., Yoon, H-J, Yhim, H-Y, Sohn, S.K., Hong, J., Lee, W-S and Baker, R.I. (2014) Similar levels of complement activation in both patients with thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome: The report from the Korean TTP registry. Blood, 124 (21).

Powell, J., Shapiro, A., Ragni, M., Negrier, C., Windyga, J., Ozelo, M., Pasi, J., Baker, R., Potts, J., Li, S., Mei, B., Pierce, G.F. and Robinson, B. (2014) Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. British Journal of Haematology, 168 (1). pp. 113-123.


Tay, J., Romeo, G., Hughes, Q. and Baker, R. (2013) Downregulation of protein S by oestrogens and miR-494. Journal of Thrombosis and Haemostasis, 11 (Supp. 2). p. 253.

Kuter, D.J., Bussel, J.B., Newland, A., Baker, R.I., Lyons, R.M., Wasser, J., Viallard, J-F, Macik, G., Rummel, M., Nie, K. and Jun, S. (2013) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy. British Journal of Haematology, 161 (3). pp. 411-423.

Tay, J.W., Romeo, G., Hughes, Q.W. and Baker, R.I. (2013) Micro-Ribonucleic Acid 494 regulation of protein S expression. Journal of Thrombosis and Haemostasis, 11 (8). pp. 1547-1555.

Powell, J.S., Pasi, K.J., Ragni, M.V., Ozelo, M.C., Valentino, L.A., Mahlangu, J.N., Josephson, N.C., Perry, D., Manco-Johnson, M.J., Apte, S., Baker, R.I., Chan, G.C., Novitzky, N., Wong, R.S., Krassova, S., Allen, G., Jiang, H., Innes, A., Li, S., Cristiano, L.M., Goyal, J., Sommer, J.M., Dumont, J.A., Nugent, K., Vigliani, G., Brennan, A., Luk, A. and Pierce, G.F. (2013) Phase 3 study of recombinant factor IX Fc fusion protein in Hemophilia B. New England Journal of Medicine, 369 (24). pp. 2313-2323.

Herrmann, R., Thom, J., Wood, A., Phillips, M, Muhammad, S. and Baker, R. (2013) Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thrombosis and Haemostasis, 111 (5). pp. 989-995.


Cheng, Y.-C., Anderson, C.D., Bione, S., Keene, K., Maguire, J.M., Nalls, M., Rasheed, A., Zeginigg, M., Attia, J., Baker, R., Barlera, S., Biffi, A., Bookman, E., Brott, T.G., Brown, R. D., Chen, F., Chen, W.-M., Ciusani, E., Cole, J.W., Cortellini, L., Danesh, J., Doheny, K., Ferrucci, L., Grazia Franzosi, M., Frossard, P., Furie, K.L., Golledge, J., Hankey, G.J., Hernandez, D., Holliday, E.G., Hsu, F.-C., Jannes, J., Kamal, A., Khan, M.S., Kittner, S.J., Koblar, S.A., Lewis, M., Lincz, L., Lisa, A., Matarin, M., Moscato, P., Mychaleckyj, J.C., Parati, E.A., Parolo, S., Pugh, E., Rost, N.S., Schallert, M., Schmidt, H., Scott, R.J., Sturm, J.W., Yadav, S., Zaidi, M., Boncoraglio, G.B., Levi, C.R., Meschia, J.F., Rosand, J., Sale, M., Saleheen, D., Schmidt, R., Sharma, P., Worrall, B. and Mitchell, B.D. (2012) Are myocardial infarction-associated single-nucleotide polymorphisms associated with ischemic stroke? Stroke, 43 (4). pp. 980-986.

Holliday, E.G., Maguire, J.M., Evans, T-J, Koblar, S.A., Jannes, J., Sturm, J.W., Hankey, G.J., Baker, R., Golledge, J., Parsons, M.W., Malik, R., McEvoy, M., Biros, E., Lewis, M.D., Lincz, L.F., Peel, R., Oldmeadow, C., Smith, W., Moscato, P., Barlera, S., Bevan, S., Bis, J.C., Boerwinkle, E., Boncoraglio, G.B., Brott, T.G., Brown, R.D., Cheng, Y-C, Cole, J.W., Cotlarciuc, I., Devan, W.J., Fornage, M., Furie, K.L., Grétarsdóttir, S., Gschwendtner, A., Ikram, M.A., Longstreth, W.T., Meschia, J.F., Mitchell, B.D., Mosley, T.H., Nalls, M.A., Parati, E.A., Psaty, B.M., Sharma, P., Stefansson, K., Thorleifsson, G., Thorsteinsdottir, U., Traylor, M., Verhaaren, B.F.J., Wiggins, K.L., Worrall, B.B., Sudlow, C., Rothwell, P.M., Farrall, M., Dichgans, M., Rosand, J., Markus, H.S., Scott, R.J., Levi, C. and Attia, J. (2012) Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nature Genetics, 44 (10). pp. 1147-1151.


Al-Tamimi, M., Gardiner, E.E., Thom, J.Y., Shen, Y., Cooper, M.N., Hankey, G.J., Berndt, M.C., Baker, R.I. and Andrews, R.K. (2011) Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke, 42 (2). pp. 498-500.


Lassen, M.R., Gallus, A., Raskob, G.E., Pineo, G., Chen, D., Ramirez, L.M. and Baker, R.I. (2010) Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. New England Journal of Medicine, 363 (26). pp. 2487-2498.

Graeme, J. and Baker, R.I. (2010) B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. The Lancet Neurology, 9 (9). pp. 855-865.

Dunkley, S., Baker, R.I., Pidcock, M., Price, J., Seldon, M., Smith, M., Street, A., Maher, D., Barrese, G., Stone, C. and Lloyd, J. (2010) Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE® in patients with von Willebrand’s disease: a prospective multi-centre study. Haemophilia, 16 (4). pp. 615-624.

Hull, Russell D., Schellong, S.M, Monreal, M., Samama, M.M., Nicol, P, Vicaut, E, Turpie, A.G., Yusen, R.D. and Baker, R. (2010) Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility. Annals of Internal Medicine, 153 (1). p. 8.

Ho, K.M., Burrell, M., Rao, S. and Baker, R. (2010) Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. British Journal of Anaesthesia, 105 (5). pp. 596-602.

Pfafferott, K., Merani, S., Rauch, A., Baccala, M., Mallal, S., Baker, R., Gaudieri, S. and Lucas, M. (2010) One step closer to a CTL-based HCV vaccine. In: The Australian Centre for HIV and Hepatitis Virology Research (ACH2) 6th National Workshop, 23 - 25 June 2010, Yarra Valley, Australia.

Bauersachs, R. and Baker, R.I. (2010) Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 363 (26). pp. 2499-2510.

Perry, J.R., Julian, J.A., Laperriere, N.J., Geerts, W., Agnelli, G., Rogers, L.R., Malkin, M.G., Sawaya, R., Baker, R., Falanga, A., Parpia, S., Finche, T. and Levine, M.N. (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Haemostasis, 8 (9). pp. 1959-1965.

Gardiner, E.E., Thom, J.Y., Al-Tamimi, M., Hughes, A., Berndt, M.C., Andrews, R.K. and Baker, R.I. (2010) Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. British Journal of Haematology, 149 (4). pp. 625-628.

Fiessinger, J. N., Bounameaux, H., Cairols, M. A., Clement, D. L., Coccheri, S., Fletcher, J. P., Hoffmann, U., Turpie, A. G. G. and Baker, R.I. (2010) Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. Journal of Thrombosis and Haemostasis, 8 (11). pp. 2369-2376.


Dunkley, S.M., Russell, S.J., Rowell, J.A., Barnes, C.D., Baker, R.I., Sarson, M.I. and Street, A.M. (2009) A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders. The Medical journal of Australia, 191 (8). pp. 460-3.

Gaudieri, S., Rauch, A., James, I., Pfafferott, K., Baker, R., Cheng, W., McCaughan, G., Shackel, N., Jeffrey, G., Mollinson, L., Mallal, S., Furrer, H., Günthard, H., Hirschel, B., Klenerman, P., Nolan, D., John, M. and Lucas, M. (2009) Co-localisation of hepatitis C virus drug-resistant mutations and immune-driven adaptations: Relevance to therapy outcome. In: 19th Annual Combined Biological Sciences Meeting 2009, 28 August 2009, Perth, Western Australia.

Lucas, M., Pfafferott, K., Baker, R., Cheng, W., Mollison, L., Baccala, M., Miczkova, S., Nazareth, S., Herrmann, S., Rauch, A. and Gaudieri, S. (2009) Correlates of infection outcome following multiple exposures to the Hepatitis C virus. In: 16th International Symposium on Hepatitis C Virus & Related Viruses, 3 - 7 October, Nice, France.

Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., Goldhaber, S.Z. and Baker, R.I. (2009) Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine, 361 (24). pp. 2342-2352.

Favaloro, E.J., Thom, J., Patterson, D., Just, S., Dixon, T., Koutts, J., Baccala, M., Rowell, J. and Baker, R. (2009) Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thrombosis Research, 123 (6). pp. 862-868.

Rauch, A., James, I., Pfafferott, K., Nolan, D., Klenerman, P., Cheng, W., Mollison, L., McCaughan, G., Shackel, N., Jeffrey, G.P., Baker, R., Freitas, E., Humphreys, I., Furrer, H., Günthard, H.F., Hirschel, B., Mallal, S., John, M., Lucas, M., Barnes, E. and Gaudieri, S. (2009) Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 50 (4). pp. 1017-1029.

Lucas, M., Pfafferott, K., Baker, R., Baccala, M., Herrmann, S. and Gaudieri, S. (2009) HCV-specific T-cell responses reflect Hepatitis C infection outcome following multiple exposures to the virus. In: Australian Centre for HIV & Hepatitis Virology Research (ACH2) 5th National Workshop, 3 - 5 June, Terrigal, NSW, Australia.

Gaudieri, S., Rauch, A., Pfafferott, K., Barnes, E., Cheng, W., McCaughan, G., Shackel, N., Jeffrey, G.P., Mollison, L., Baker, R., Furrer, H., Günthard, H.F., Freitas, E., Humphreys, I., Klenerman, P., Mallal, S., James, I., Roberts, S., Nolan, D. and Lucas, M. (2009) Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 49 (4). pp. 1069-1082.

Hooper, A.J.., Robertson, K., Ng, L., Kattampallil, J.S., Latchem, D., Willsher, P.C., Thom, J., Baker, R.I. and Burnett, J.R. (2009) A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. Clinica Chimica Acta, 409 (1-2). pp. 136-139.

Pearson, L., Thom, J., Adams, M., Oostryck, R., Krueger, R., Yong, G. and Baker, R. (2009) A rapid flow cytometric technique for the detection of platelet-monocyte complexes, activated platelets and platelet-derived microparticles. International Journal of Laboratory Hematology, 31 (4). pp. 430-439.


Gardiner, E.E., Al-Tamimi, M., Mu, F.-T., Karunakaran, D., Thom, J.Y., Moroi, M., Andrews, R.K., Berndt, M.C. and Baker, R.I. (2008) Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 6 (7). pp. 1175-1182.

Gardiner, E.E., Karunakaran, D., Arthur, J.F., Mu, F.-T., Powell, M.S., Baker, R.I., Hogarth, P.M., Kahn, M.L., Andrews, R.K. and Berndt, M.C. (2008) Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing Fc RIIa. Blood, 111 (1). pp. 165-174.

Buller, H., Deitchman, D., Prins, M., Segers, A. and Baker, R.I. (2008) Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis, 6 (8). pp. 1313-1318.

Pfafferott, K., Gaudieri, S., Naidoo, K., Rauch, A., Baccala, M., Baker, R., Mallal, S. and Lucas, M. (2008) Population based genetic approach identifies novel hepatitis C targets of the immune response. In: 20th Annual Australasian Society for HIV Medicine Conference, 17 - 20 September, Perth, Western Australia.

P’ng, S., Carnley, B., Baker, R.I., Kontorinis, N. and Cheng, W. (2008) Undiagnosed Myeloproliferative Disease in Cases of Intra-Abdominal Thrombosis: The Utility of the JAK2 617F Mutation. Clinical Gastroenterology and Hepatology, 6 (4). pp. 472-475.

Flanagan, D., MacLellan, D., Gibbs, H., Baker, R. and Fletcher, J. (2008) The insidious hazard of hospitalisation: Venous thromboembolism. Medicine Today, 9 (9). pp. 16-26.

This list was generated on Sat Oct 21 10:24:22 2017 UTC.